-
Product Insights
NewNet Present Value Model: Ikena Oncology Inc’s IK-595
Empower your strategies with our Net Present Value Model: Ikena Oncology Inc's IK-595 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-595 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IK-595 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IK-595 in Solid Tumor Drug Details: IK-595 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Hepatitis D report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Hepatitis D Drug Details: Ropeginterferon...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bimekizumab in Psoriatic Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bimekizumab in Psoriatic Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bimekizumab in Psoriatic Arthritis Drug Details: Bimekizumab (Bimzelx) is a humanised IgG1monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Grapiprant in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Grapiprant in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Grapiprant in Colorectal Cancer Drug Details: Grapiprant (RQ-0000007, RQ-7, MR10A7) is under...
-
Product Insights
NewMeningioma – Drugs In Development, 2024
Empower your strategies with our Meningioma – Drugs In Development, 2024 report and make more profitable business decisions. A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid, and pia mater. Most meningiomas (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of...
-
Product Insights
NewLung Adenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...
-
Product Insights
NewSalivary Gland Cancer – Drugs In Development, 2024
Empower your strategies with our Salivary Gland Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Salivary gland cancer refers to malignant tumors that develop in the tissues of the salivary glands, which produce saliva to aid in digestion and maintain oral health. These glands are located in various areas of the mouth and throat, including the parotid glands (the largest salivary glands), submandibular glands, sublingual glands, and numerous minor glands throughout the mouth. Salivary gland cancers...
-
Product Insights
NewVulvar Cancer – Drugs In Development, 2024
Empower your strategies with our Vulvar Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. The Vulvar Cancer drugs in...
-
Product Insights
NewVaginal Cancer – Drugs In Development, 2024
Empower your strategies with our Vaginal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Vaginal cancer is a rare cancer that occurs in the vagina. Symptoms includes watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, and vaginal bleeding. Risk factors include age, smoking, HIV infection, and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy, and chemotherapy. The Vaginal Cancer drugs in development market research report provide comprehensive information...